Home » LONGPORT COMPLETES DEVELOPMENT OF ADDITIONAL DERMATOLOGY PROBES FOR EPISCAN-I-200 SYSTEM
LONGPORT COMPLETES DEVELOPMENT OF ADDITIONAL DERMATOLOGY PROBES FOR EPISCAN-I-200 SYSTEM
Longport, Inc. (OTCBB:LPTI), a medical technology specialist in high resolution ultrasound imaging, announced the development of additional dermatology probes for its EPISCAN-I-200 system. Longport has been working over the last few months on a program to improve the dermal imaging capability of the EPISCAN, which has resulted in a number of new probe configurations with center frequencies up to 50MHz.
MENAFN (http://menafn.com/qn_news_story.asp?StoryId=CqWQFqbKbmJm1yJaZnZC)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May